Johnson & Johnson is exiting the insulin pump market.
The company said it would discontinue manufacturing and selling the Animas, Vibe and OneTouch Ping insulin pumps, offering patients the option to transfer to Medtronic plc products instead.
While the company will continue to provide customer service, training and warranty support, it has already stopped selling the products in the U.S. and Canada and is working on a decision and timing to exit other countries.
Earlier this year, Johnson & Johnson said it was looking to sell its consumer-oriented diabetes devices business after steady declines in the segment since 2011.
That announcement came a year after the company said it was restructuring its medical device businesses as part of a plan to save up to $1 billion per year through 2018.